()
 
 

Overview

MediciNova is developing eight unique, differentiated small molecules for ten different therapeutic indications. These drug candidates offer significant potential improvements over current standards of care for a variety of diseases and conditions. MediciNova's development programs include potential treatments for asthma, multiple sclerosis, cancer, and insomnia. Most of these programs are in advanced clinical testing. MediciNova is significantly undervalued. To reach this conclusion, we employed what we believe is a rather conservative valuation methodology that is explained in our report. We rate the Company's shares a Strong Speculative Buy. Based on our analysis, a target price could include a wide range of valuations above the Company's current share price. However, our experience leads us to believe that, with the potential of its development programs and expected milestones, MediciNova could trade for $20 a share by the end of the year. This rating assumes that the Company will achieve ...


Contact Information

4350 La Jolla Village Drive
Suite 950
San Diego, CA 92122

tel: 858-373-1500
fax: 858-373-7000
http://www.medicinova.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $48.7M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.